Tags

Type your tag names separated by a space and hit enter

SARS-CoV-2 Vaccines: Status Report.
Immunity. 2020 Apr 14; 52(4):583-589.I

Abstract

SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population.

Links

PMC Free PDF

Authors+Show Affiliations

Amanat F
Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Krammer F
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: florian.krammer@mssm.edu.

MeSH

AnimalsBetacoronavirusCOVID-19COVID-19 VaccinesChinaClinical Trials as TopicCoronavirusCoronavirus InfectionsDisease Models, AnimalDrug DevelopmentHumansPandemicsPneumonia, ViralSARS-CoV-2Time FactorsViral Vaccines

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review

Language

eng

PubMed ID

32259480

Citation

Amanat, Fatima, and Florian Krammer. "SARS-CoV-2 Vaccines: Status Report." Immunity, vol. 52, no. 4, 2020, pp. 583-589.
Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020;52(4):583-589.
Amanat, F., & Krammer, F. (2020). SARS-CoV-2 Vaccines: Status Report. Immunity, 52(4), 583-589. https://doi.org/10.1016/j.immuni.2020.03.007
Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020 Apr 14;52(4):583-589. PubMed PMID: 32259480.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SARS-CoV-2 Vaccines: Status Report. AU - Amanat,Fatima, AU - Krammer,Florian, Y1 - 2020/04/06/ PY - 2020/3/3/received PY - 2020/3/15/revised PY - 2020/3/17/accepted PY - 2020/4/8/pubmed PY - 2020/4/25/medline PY - 2020/4/8/entrez SP - 583 EP - 589 JF - Immunity JO - Immunity VL - 52 IS - 4 N2 - SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population. SN - 1097-4180 UR - https://www.unboundmedicine.com/medline/citation/32259480/SARS_CoV_2_Vaccines:_Status_Report_ DB - PRIME DP - Unbound Medicine ER -